Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Medivir on its divestment of BioPhausia to Karo Pharma
Mandate

Vinge advises Medivir on its divestment of BioPhausia to Karo Pharma

November 03, 2016

Medivir AB (publ) (Nasdaq Stockholm) has entered into an agreement with Karo Pharma AB (publ) (Nasdaq Stockholm) regarding the sale of Medivir’s subsidiary BioPhausia (Nordic Brands) to Karo Pharma. The purchase price is SEK 908 million and the transaction is expected to close by mid-December 2016.
 
Vinge advises Medivir. The Vinge team includes Erik Sjöman, Anna Edström, Mattias Sköld, Dain Hård Nevonen, Rikard Lindahl and Ludvig Frithiof, and Fredrik Dahl and Sara Strandberg (employment law).

Related

Vinge advises Oral Care in connection with the acquisition of Dutch dental care provider De Tandartsengroep (DTG)

DTG operates 31 clinics and 8 dental laboratories in the Netherlands. Oral Care is a portfolio company of Axcel VI and operates a network of dental clinics in Sweden, Norway and the Netherlands. To support this expansion, Axcel VII is joining Axcel VI as a shareholder in Oral Care.
February 19, 2025

Vinge advises Gotlandsbolaget in connection with off-take agreement regarding biogas

 Vinge has advised Rederiaktiebolaget Gotland (Gotlandsbolaget) in connection with the entry into of a strategic off-take agreement, which secures the long-term supply of biogas for the Gotland ferry service traffic.
February 17, 2025

Vinge advises HAKI Safety AB in connection with the acquisition of Trimtec

 Trimtec is a Swedish distributor of high-tech precision equipment.
February 14, 2025